Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YNYQT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CBP-1008
|
|||||
| Synonyms |
CBP1008; CBP 1008
Click to Show/Hide
|
|||||
| Organization |
Coherent Biopharma Suzhou Co. Ltd.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 5 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Phase 2
Epithelial ovarian cancer [ICD11:2B5D]
Phase 2
Ovarian cancer [ICD11:2C73]
Phase 2
Platinum resistant fallopian tube cancer [ICD11:2C74]
Phase 2
Platinum resistant peritoneal cancer [ICD11:2C51]
Phase 2
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Folate receptor alpha (FOLR1); Transient receptor potential cation channel subfamily V member 6 (TRPV6)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) |
15.90% (all)
33.30% (FOLR1/TRPV6 high) |
|||
| Patients Enrolled |
Patients with platinum-resistant ovarian cancer (OC), metastatic triple negative breast cancer (TNBC) and received median 3 prior regimens.
|
||||
| Administration Dosage |
0.15, 0.17, 0.18 mg/kg day1 and day15; q28d.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04740398 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1a/1b, open-label, multi-center, first in human and expansion study to assess the safety, tolerance, and pharmacokinetics of the novel antitumor agent CBP-1008 in patients with advanced solid tumors. | ||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.